Insulet (NASDAQ:PODD) Issues Earnings Results

Insulet (NASDAQ:PODD) posted its quarterly earnings results on Wednesday. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.21, FiscalAI reports. The firm had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.17 EPS. Insulet updated its FY 2026 guidance to 6.460- EPS.

Here are the key takeaways from Insulet’s conference call:

• Strong second-quarter performance: Revenue increased 23% on a constant-currency basis to $802 million, while adjusted operating margin expanded 140 basis points to 19.3% and adjusted EPS rose 41.5% to $1.66.
• Insulet lowered its 2026 outlook to 20%–22% total company revenue growth and 17%–19% U.S. Omnipod growth, citing weaker-than-expected type 2 customer retention and utilization, slower new customer starts, and somewhat lower anticipated pricing.
• The company is expanding customer support, revising sales-force incentives to emphasize retention, refining sampling, and scaling Omnipod Discover to improve onboarding and retention during the critical first 90 days of therapy.
• International momentum remains strong, with full-year international Omnipod growth guidance raised to 30%–32%; the company also reported coverage additions for 6.5 million lives and reduced prior-authorization barriers for approximately 10 million lives.
• Insulet continues to invest in its pipeline, including Omnipod 6 and a fully closed-loop type 2 system, with a 510(k) submission for the latter still expected in 2027; formal 2027 guidance and an updated long-range outlook will come with fourth-quarter results.

Insulet Stock Down 20.1%

Shares of Insulet stock traded down $33.56 on Wednesday, hitting $133.26. The company had a trading volume of 7,154,664 shares, compared to its average volume of 1,312,241. Insulet has a 1 year low of $126.40 and a 1 year high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The stock has a 50 day moving average of $155.56 and a 200-day moving average of $195.01. The stock has a market capitalization of $9.23 billion, a price-to-earnings ratio of 30.99, a P/E/G ratio of 1.16 and a beta of 1.10.

Insider Activity

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.36% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PODD. NewEdge Advisors LLC boosted its position in Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 64 shares during the last quarter. Cresset Asset Management LLC raised its stake in shares of Insulet by 7.3% during the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock worth $813,000 after purchasing an additional 177 shares during the period. Cerity Partners LLC raised its stake in shares of Insulet by 68.7% during the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock worth $5,423,000 after purchasing an additional 7,030 shares during the period. Sei Investments Co. boosted its holdings in shares of Insulet by 27.4% in the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after buying an additional 29,584 shares during the last quarter. Finally, Treasurer of the State of North Carolina boosted its holdings in shares of Insulet by 2.5% in the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after buying an additional 791 shares during the last quarter.

Analyst Ratings Changes

Several research firms have recently weighed in on PODD. UBS Group lowered shares of Insulet from a “buy” rating to a “neutral” rating and set a $174.00 price objective for the company. in a research note on Tuesday, July 28th. Stifel Nicolaus cut their target price on shares of Insulet from $250.00 to $225.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Royal Bank Of Canada reduced their price target on shares of Insulet from $280.00 to $245.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft started coverage on shares of Insulet in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $190.00 price target for the company. Finally, JPMorgan Chase & Co. cut their price objective on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a research report on Thursday, May 7th. Twenty analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $226.38.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet exceeded second-quarter expectations across key metrics. Adjusted earnings were $1.66 per share versus consensus estimates of approximately $1.44-$1.45, while revenue reached $801.7 million compared with expectations of $787.4 million. Revenue increased 23.5% year over year, and earnings rose from $1.17 per share in the prior-year quarter. Insulet Q2 earnings report
• Positive Sentiment: The quarterly performance indicates continued demand for Insulet’s Omnipod products and operational leverage, although investors focused more heavily on the forward outlook than on the beat. Insulet beats Q2 earnings and revenue estimates

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.